Adlai Nortye Ltd. (NASDAQ:ANL) Sees Significant Decrease in Short Interest

Adlai Nortye Ltd. (NASDAQ:ANL) was the target of a significant drop in short interest in July. As of July 15th, there was short interest totalling 11,200 shares, a drop of 8.9% from the June 30th total of 12,300 shares. Based on an average trading volume of 13,100 shares, the short-interest ratio is currently 0.9 days.

Adlai Nortye Trading Up 1.5 %

Shares of Adlai Nortye stock traded up $0.05 during trading on Wednesday, hitting $3.49. The stock had a trading volume of 1,100 shares, compared to its average volume of 10,018. The business has a fifty day moving average of $4.65 and a two-hundred day moving average of $8.08. Adlai Nortye has a fifty-two week low of $3.01 and a fifty-two week high of $19.30.

Institutional Investors Weigh In On Adlai Nortye

An institutional investor recently raised its position in Adlai Nortye stock. Cantor Fitzgerald L. P. raised its holdings in shares of Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 40,310 shares of the company’s stock after buying an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 as of its most recent SEC filing. 35.21% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Adlai Nortye in a report on Thursday, June 20th.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.